Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 84

1.

Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer.

Kim TW, Elme A, Park JO, Udrea AA, Kim SY, Ahn JB, Valencia RV, Krishnan S, Manojlovic N, Guan X, Lofton-Day C, Jung AS, Vrdoljak E.

Clin Colorectal Cancer. 2018 Mar 21. pii: S1533-0028(17)30529-7. doi: 10.1016/j.clcc.2018.03.008. [Epub ahead of print]

2.

Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2- metastatic breast cancer.

Ban M, Miše BP, Majić A, Dražić I, Vrdoljak E.

Future Oncol. 2018 Mar;14(6):537-544. doi: 10.2217/fon-2017-0491. Epub 2017 Nov 22.

PMID:
29164917
3.
4.

Biosimilars in the Treatment of Breast Cancer.

Balic M, Bartsch R, Bauernhofer T, Vrbanec D, Vrdoljak E.

Breast Care (Basel). 2017 Jul;12(3):192-194. doi: 10.1159/000477926. Epub 2017 Jun 13. No abstract available.

5.

Is macrocytosis a potential biomarker of the efficacy of dose-dense paclitaxel-carboplatin combination therapy in patients with epithelial ovarian cancer?

Boraska Jelavić T, Boban T, Brčić L, Vrdoljak E.

Anticancer Drugs. 2017 Sep;28(8):922-927. doi: 10.1097/CAD.0000000000000538.

PMID:
28678030
6.

Prognostic value of vitamin D receptor and insulin-like growth factor receptor 1 expression in triple-negative breast cancer.

Soljic M, Mrklic I, Tomic S, Omrcen T, Sutalo N, Bevanda M, Vrdoljak E.

J Clin Pathol. 2018 Jan;71(1):34-39. doi: 10.1136/jclinpath-2016-204222. Epub 2017 Jun 29.

PMID:
28663327
7.

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators.

N Engl J Med. 2017 Jul 13;377(2):122-131. doi: 10.1056/NEJMoa1703643. Epub 2017 Jun 5. Erratum in: N Engl J Med. 2017 Aug 17;377(7):702.

8.

Prognostic significance of MAPK, Topo IIα and E-cadherin immunoexpression in ovarian serous carcinomas.

Sundov D, Petric Mise B, Mrklic I, Bacic B, Vrdoljak E, Tomic S.

Neoplasma. 2017;64(2):289-298. doi: 10.4149/neo_2017_217.

PMID:
28052682
9.

Factors influencing pain therapy for metastatic cancer patients in Bosnia and Herzegovina.

Tica Sedlar I, Čale S, Parić A, Perić M, Jurčić J, Vrdoljak E.

Acta Med Acad. 2016 Nov;45(2):104-120. doi: 10.5644/ama2006-124.166.

10.

Bone health and adherence to vitamin D and calcium therapy in early breast cancer patients on endocrine therapy with aromatase inhibitors.

Bošković L, Gašparić M, Petković M, Gugić D, Lovasić IB, Soldić Ž, Miše BP, Dabelić N, Vazdar L, Vrdoljak E.

Breast. 2017 Feb;31:16-19. doi: 10.1016/j.breast.2016.10.018. Epub 2016 Oct 27.

PMID:
27810693
11.

Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer.

Vrdoljak E, Marschner N, Zielinski C, Gligorov J, Cortes J, Puglisi F, Aapro M, Fallowfield L, Fontana A, Inbar M, Kahan Z, Welt A, Lévy C, Brain E, Pivot X, Putzu C, González Martín A, de Ducla S, Easton V, von Minckwitz G.

Ann Oncol. 2016 Nov;27(11):2046-2052. Epub 2016 Aug 8.

PMID:
27502725
12.

Three radiation-induced metachronous pelvic tumors in a patient who underwent radiotherapy for cervical cancer: a case report.

Boban M, Tomic S, Sulic M, Vrdoljak E.

Tumori. 2016 Nov 11;102(Suppl. 2). doi: 10.5301/tj.5000518.

PMID:
27133229
13.

A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer.

Kim TW, Elme A, Kusic Z, Park JO, Udrea AA, Kim SY, Ahn JB, Valencia RV, Krishnan S, Bilic A, Manojlovic N, Dong J, Guan X, Lofton-Day C, Jung AS, Vrdoljak E.

Br J Cancer. 2016 Nov 8;115(10):1206-1214. doi: 10.1038/bjc.2016.309. Epub 2016 Oct 13.

14.

Retrospective analysis of efficacy of trastuzumab in adjuvant treatment of HER 2 positive early breast cancer - single institution experience.

Ban M, Viculin J, Tomic S, Capkun V, Strikic A, Mise BP, Utrobicic I, Vrdoljak E.

Neoplasma. 2016;63(5):761-7. doi: 10.4149/neo_2016_513.

PMID:
27468880
15.

Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement.

Vrdoljak E, Bodoky G, Jassem J, Popescu RA, Mardiak J, Pirker R, Čufer T, Bešlija S, Eniu A, Todorović V, Kubáčková K, Kurteva G, Tomašević Z, Sallaku A, Smichkoska S, Bajić Ž, Šikić BI.

Oncologist. 2016 Oct;21(10):1183-1190. Epub 2016 Jul 8.

16.

Optimisation of breast cancer patients' follow-up - potential way to improve cancer care in transitional countries.

Bošković L, Gašparić M, Petrić Miše B, Petković M, Gugić D, Ban M, Jazvić M, Dabelić N, Belac Lovasić I, Vrdoljak E.

Eur J Cancer Care (Engl). 2017 Jul;26(4). doi: 10.1111/ecc.12514. Epub 2016 May 5.

PMID:
27145728
17.

GUIDELINES FOR THE PREVENTION, DETECTION AND THERAPY OF VITAMIN D DEFICIENCY IN ADULTS.

Vranešić Bender D, Giljević Z, Kušec V, Laktašic Žerjavić N, Bošnjak Pašic M, Vrdoljak E, Lkinas Kelećić Dina, Reiner Ž, Anić B, Krznarić Ž.

Lijec Vjesn. 2016 May;138(5-6):121-132.

PMID:
29182823
18.

Pharmacoeconomic and clinical implications of sequential therapy for metastatic renal cell carcinoma patients in Central and Eastern Europe.

Vrdoljak E, Torday L, Szczylik C, Kharkevich G, Bavbek S, Sella A.

Expert Opin Pharmacother. 2016;17(1):93-104. doi: 10.1517/14656566.2016.1107043. Epub 2015 Nov 30.

PMID:
26619144
20.

[CLINICAL GUIDELINES FOR DIAGNOSIS, TREATMENT AND MONITORING OF PATIENTS WITH INVASIVE BREAST CANCER--CROATIAN ONCOLOGY SOCIETY].

Šeparović R, Ban M, Silovska T, Oresković LB, Soldić Ž, Podolski P, Pleština S, Gugić D, Petković M, Jakić-Razumović J, Vojnović Z, Miše BP, Tomić S, Stanec Z, Vrdoljak DV, Drinković I, Brkljačić B, Mustać E, Utrobičić I, Vrdoljak E; CROATIAN ONCOLOGY SOCIETY.

Lijec Vjesn. 2015 May-Jun;137(5-6):143-9. Croatian.

PMID:
26380471

Supplemental Content

Loading ...
Support Center